Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by grosdavidon May 01, 2020 12:53pm

122 Views

Post# 30976642

RE:the retail investor got scammed

Pathetic post. Look at the MACRO-economics, market is down solid since yesterday.

All stocks are red, even Gilead Scienceswith their "soon to market product". No one got scammed, leave the boat if you can't handle it.

We should put you on a Ifenprodil so those lungs could be breathe a little more hahaha!

Long.

Bullboard Posts

Unique Battery Metals opportunity in Quebec